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Purpose: Several studies have shown that the intralesional concentration of rifampicin in osteoarticular tuberculosis
is typically at a subtherapeutic level. Sustained or controlled release by novel drug delivery systems has been
investigated to maintain an effective rifampicin concentration, but the local administration of rifampicin remains
controversial. Additionally, it is still unclear whether high-dose rifampicin could kill rifampicin-resistant Mycobacterium
tuberculosis. The aim of this study was to assess the in vitro killing effect of high-concentration rifampicin on
rifampicin-resistant M. tuberculosis isolated from patients with osteoarticular tuberculosis.
Methods: A set of 18 rifampicin-resistant M. tuberculosis isolates by the BACT/MGIT 960 system from patients with
osteoarticular tuberculosis was collected for further study. The detection of rpoB gene mutations was performed using
non-fluorescent, low-density DNA microarrays to determine the resistant mechanism. Following secondary culture,
susceptibility to gradient concentrations of rifampicin (2 to 256 μg/ml) was tested; these concentrations are attainable
for prolonged periods of local chemotherapy. The relationship between microbial killing by high-dose rifampicin and
rpoB gene mutations was analyzed.
Results: Mutations in the rifampicin resistance-determining region (RRDR) of the rpoB gene were identified in 17
isolates (94.4%); one strain exhibited no mutations in this region. The most prevalent mutation sites were in codons 531
(55.56%), 516 (16.67%), 526 (11.11%), and 513 (11.11%). Isolates with mutations in the rpoB gene were highly resistant
to rifampicin, 11 of which had minimal inhibitory concentrations (MICs) exceeding 256 μg/ml (not determined). The
MICs for the remaining seven resistant isolates were between 32 and 256 μg/ml. Particularly in less rifampicin-resistant
M. tuberculosis strains, growth was inhibited at high concentrations.
Conclusion: Increasing the rifampicin concentration may optimize this drug’s antituberculous effect, even against
some rifampicin-resistant isolates, if systemic and local toxic effects can be minimized.
Keywords: Rifampicin, Drug resistance, Osteoarticular tuberculosis, rpoB geneIntroduction
One-third of the world’s population is infected with
Mycobacterium tuberculosis. There were almost 9 mil-
lion new cases in 2011 and 1.4 million tuberculosis (TB)
deaths, with China accounting for nearly 17% of the
worldwide TB burden, second only to India in the number* Correspondence: david-feifei@163.com; xjzslw@163.com
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unless otherwise stated.of TB patients [1]. Extra-pulmonary TB was usually non-
contagious, and it did not attract much public attention.
Unfortunately, the incidence of osteoarticular tuberculosis
has risen concurrently with that of pulmonary tubercu-
losis. Osteoarticular tuberculosis condition requires more
attention, especially considering the large number of af-
fected people and its resultant disability and mortality [2].
Additionally, multidrug-resistant tuberculosis (MDR-TB)
is on the rise worldwide, posing a significant threat to the
world’s population.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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agent in 1963, it has been the cornerstone of drug regi-
mens for the treatment of tuberculosis. Studies have
demonstrated variable bioavailability and low plasma
concentrations of rifampicin [3], as well as intralesional
concentrations of rifampicin and pyrazinamide in osteoar-
ticular tuberculosis at mostly subtherapeutic levels [4].
Therefore, rifampicin has been associated with clinical fail-
ure and drug resistance.
In some drug resistance test by absolute concentration
method, low-level resistance of M. tuberculosis to rifampi-
cin was overcome by an increase in the drug concentration
from 50 to 250 μg/ml, implying that the drug’s antituber-
culous effect can be optimized by increasing the dose [5].
The local administration of rifampicin may be an effective
clinical approach to treat osteoarticular tuberculosis. Our
study in vitro aimed to determine the killing effect of high-
concentration rifampicin on rifampicin-resistant isolates
from patients with osteoarticular tuberculosis.
Materials and methods
Bacterial strain isolation
A total of 198 patients with osteoarticular tuberculosis
were admitted to Southwest Hospital (Chongqing, China)
and the Chongqing Infectious Diseases Medical Center
(Chongqing, China) from 1 December 2006 to 1 December
2011. The study was approved by the Ethics Committee of
Southwest Hospital. Written informed consent was ob-
tained from all of the patients. Cold abscess and caseous
tissue necrosis samples were collected during surgery.
These specimens were processed according to standard
protocols. The same amount of each concentrated sample
(0.5 ml) was inoculated into vials for use with the BacT/
ALERT 3D Microbial Detection System (bioMerieux,
France) containing modified Middlebrook 7H9 broth sup-
plemented with an antibiotic. All mycobacterial cultures
were incubated at 37°C. The detection of mycobacterial
growth by the BacT/ALERT 3D Microbial Detection Sys-
tem is based on colorimetric detection of carbon dioxide,
and the cultures are continuously monitored by the auto-
mated system. Mycobacterial growth was also verified by
Ziehl-Neelsen staining and microscopy [6-9]. Drug suscep-
tibility testing was performed on the first isolate from each
patient using the absolute concentration method on Löw-
enstein-Jensen (L-J) medium. This testing included 11
first- and second-line drugs. For all drugs, except pyrazina-
mide, the following critical concentrations were used: 50
and 250 μg/ml rifampicin, 1 and 10 μg/ml isoniazid, 5 and
50 μg/ml ethambutol, 10 and 100 μg/ml streptomycin, 5
and 50 μg/ml levofloxacin, 1 and 10 μg/ml PAS, 25 and
100 μg/ml protionamide, 0.1 and 1 μg/ml pasiniazid, 50
and 250 μg/ml rifapentine, 10 and 100 μg/ml capreomycin,
and 10 and 100 μg/ml amikacin. The L-J slants were
inspected weekly for growth over a total of 8 weeks [10].A set of 18 rifampicin-resistant M. tuberculosis strains
were obtained and recovered using the BacT/ALERT 3D
Microbial Detection System. The standard M. tubercu-
losis strain H37Rv (from the National Institutes for Food
and Drug Control of China) was employed as a control.
Each culture was used for susceptibility testing within
3 days after the instrument detected a positive signal.
Detection of rpoB mutations using a DNA probe array
The template DNA for molecular sequencing was pre-
pared by heat-killing mycobacteria at 95°C for 30 min,
sonicating the bacteria at room temperature for
25 min, and centrifuging the sample at 5,000 rpm for
1 min. The supernatant was then stored at −20°C until
needed.
A commercial PCR-based reverse hybridization line
probe assay (M. tuberculosis Drug Resistance Detection
Array Kit; CapitalBio Corporation, China) using biotinyl-
ated primers was performed manually according to the
manufacturer’s instructions. This assay consists of specific
oligonucleotides immobilized at known locations on
membrane strips and hybridized under strictly controlled
conditions with a biotin-labeled PCR product (Table 1).
The fluorescent signal emitted by the target bound to
the array was detected at a pixel resolution of 3 μm
using a LuxScan™ 10 K Microarray Scanner (CapitalBio).
Probe array cell intensities, nucleotide base calls, and
mutation determinations and reports were generated
using GeneChip software (CapitalBio) [11-14].
Rifampicin susceptibility testing of rifampicin-resistant
M. tuberculosis
A stock solution of rifampicin was prepared by dissolv-
ing 80 mg of rifampicin in 1 ml of DMSO to attain a
final concentration of 80 mg/ml. This solution was then
aliquoted and stored at −20°C. Eight dilutions (bioMer-
ieux) were prepared by diluting the rifampicin stock solu-
tion with modified Middlebrook 7H9 to achieve the
desired concentrations by the broth microdilution method
(serial twofold dilutions of rifampicin, ranging from 2 to
256 mg/ml). Culture vials containing antibiotics, as well as
one drug-free control vial, were inoculated to reach a final
concentration of approximately 3 × 105 to 3 × 106 cfu/ml.
All culture vials were incubated in the BacT/ALERT 3D
Microbial Detection System instrument and continu-
ously monitored until the results, indicating suscepti-
bility or resistance, were automatically interpreted and
reported by the system based on predefined algorithms.
These algorithms compared growth in the drug-containing
tubes to that in the growth control tube. Next, 0.5 ml of
MB/BacT Antibiotic Supplement (bioMerieux) was added
to the BacT/ALERT culture vials. These vials were tested
daily for up to 12 days, which is the maximum incubation
time for antimycobacterial susceptibility testing. Ziehl-
Table 1 Schematic diagram of the DNA probe array for
rpoB detection
1 2 3 4 5 6 7 8 9 10
1 QC EC
2 BC rpoB-IC
3 Mycobacterium M. tuberculosis
4 511-WT 511 T→ C
5 513-WT 513 C→ A
6 516-WT 513 A→ C
7 533-WT 533 T→ C
8 531-WT 531 C→ T
9 526-WT 531 C→ G
10 526 C→ T 526 C→ G
11 526 A→ T 526 A→ G
12 516 A→ T 516 G→ T
13 516 A→ G NC
14 EC QC
All probes (511, 513, 516, 531, 526, and 533) were immobilized horizontally
five times. QC, quality control; EC, external control; BC, blank control; NC,
negative control; IC, internal control; WT, wild-type.
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fast bacilli in all positive media.
Statistical analysis
The results were analyzed using Wilcoxon’s signed rank
test. P values of less than 0.05 were considered statisti-
cally significant. All analyses were carried out using
SPSS 13.0 software.
Results
In this study, mutations in the rifampicin resistance-
determining region (RRDR) of the rpoB gene were identi-
fied in 17 (94.4%) of the 18 rifampicin-resistant isolates,
with one rifampicin-resistant strain exhibiting no muta-
tions in this region. The most prevalent mutation sites were
in codons 531 (55.56%), 516 (16.67%), 526 (11.11%), and
513 (11.11%) (Figure 1). High-level rifampicin-resistant
strains (resistant to 250 μg/ml) exhibited a higher mutation
frequency at 531-Ser than low-level rifampicin-resistant
strains (resistant to 50 μg/ml) (P < 0.05). The growth of
the H37Rv strain was inhibited at rifampicin concentra-
tions ≤0.25 μg/ml, indicating drug susceptibility.
The relationship between the degree of resistance to
rifampicin and the mutation site was characterized by
the minimal inhibitory concentration (MIC) test. Isolates
with mutations in the rpoB gene were highly resistant to
rifampicin, 11 of which had MICs exceeding 256 μg/ml
(not determined), and 81.81% (9/11) had mutation in co-
dons 531. The MICs for the remaining seven resistant
isolates were between 32 and 256 μg/ml, and only
14.29% (1/7) had mutation in codons 531. Particularlyin low-level rifampicin-resistant M. tuberculosis strains,
growth was inhibited at high concentrations (Table 2).
Discussion
Rifampicin is a key component of standard antitubercu-
losis regimens. This drug exhibits a significant early bac-
tericidal effect on metabolically active M. tuberculosis.
However, data suggest that the standard rifampicin dose
is probably at the lower limit of optimal efficacy. The
currently applied dose of 10 mg of drug per kilogram of
body weight may only result in low plasma concentrations
of rifampicin [3]. Several studies have also shown that the
intralesional concentration of rifampicin in osteoarticular
tuberculosis is mostly subtherapeutic. Jutte and colleagues
found that the penetration of isoniazid in tuberculous
pleural effusion and psoas abscess was always sufficient,
while the penetration of rifampicin was mostly below the
desired ratio, and that of pyrazinamide was ten times too
low on average [4]. Therefore, rifampicin may potentially
fail in patients with active disease and may even contribute
to the increasing resistance to antituberculosis drugs.
Unfortunately, the causes of poor or variable bioavail-
ability of rifampicin are not clearly understood. This prob-
lem is particularly evident when rifampicin is present in
antituberculous fixed-dose combination products, which
is a matter of serious concern. The enhanced decompos-
ition of rifampicin in the presence of isoniazid in the
stomach after ingestion may be a key reason for the prob-
lem. Crystalline changes in the drug and inadequate blood
supply to the tuberculous lesion are also cited as the prin-
cipal reasons [15].
The mechanisms underlying drug resistance are often
multifaceted and may include not only chromosomal
mutations but also induction or the presence of efflux
pumps, and even antagonism of the component drugs in
combination therapy. Mutations in the rpoB gene, en-
coding the β subunit of the bacterial RNA polymerase,
have been strongly associated with rifampicin (RMP)-re-
sistant phenotypes in multiple study populations. rpoB
mutations are most common in an 81-bp region called
the RRDR. Up to 90% of RMP-resistant strains carry
RRDR mutations at codons 516, 526, or 531 [16]. In this
study, the majority (94.44%) of rifampicin-resistant M.
tuberculosis isolates were found to contain point muta-
tions at codons 531 (55.56%), 516 (16.67%), 526 (11.11%),
or 513 (11.11%), which are located in the core region of
the rpoB gene. Codons 531 and 526 are the most common
sites of nucleotide substitutions worldwide; the difference
between the worldwide average and our data may be at-
tributed to sampling error and geographical genetic differ-
ences in RMP-resistant M. tuberculosis strains [17,18].
The use of certain antituberculous drugs for the treat-
ment of low-level rifampicin-resistant M. tuberculosis re-
mains controversial. To assess the feasibility of isoniazid
Figure 1 Detection of M. tuberculosis rpoB mutants using a DNA probe array. (a) Wild-type without high hybridization signal of the
mutated probe as control. (b) RMP resistance with the rpoB 531 (TCG→ TTG) mutation (higher hybridization signal, red rectangle). (c) RMP
resistance test: rpoB 526 (CAC→ GAC) mutation (red rectangle). (d) RMP resistance with the rpoB 516 (GAC→ GGC) mutation (red rectangle).
(e) RMP resistance with the rpoB 531 (CAA→ CCA) mutation (red rectangle).
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losis, Schaaf and colleagues measured the minimal in-
hibitory concentration of isoniazid in isoniazid-resistant
M. tuberculosis isolates obtained from children. They
found that for 80% of the isoniazid-resistant strains forTable 2 M. tuberculosis rpoB wild-type and mutant
isolates analyzed using the rpoB probe array
Clinical isolates Resistance phenotype MIC (μg/ml) Mutated
codon(s)
1 L 32 WT
2 L 64 516 A→ G
3 L 64 516 A→ G
4 L 128 513 A→ C
5 H 128 526 C→ G
6 H 256 513 A→ C
7 H 256 531 C→ T
8 H ND 531 C→ T
9 H ND 531 C→ T
10 H ND 531 C→ T
11 H ND 531 C→ T
12 H ND 531 C→ T
13 H ND 531 C→ T
14 H ND 531 C→ T
15 H ND 531 C→ T
16 H ND 531 C→ G
17 H ND 526 C→ T
18 H ND 516 A→ G
H37Rv S 0.25 WT
S, susceptible to rifampicin; L, low-level resistance to rifampicin (resistant to
50 μg/ml rifampicin); H, high-level resistance to rifampicin (resistant to 250 μg/ml
rifampicin); ND, not determined; WT, wild-type.which the MIC was relatively low, high-dose INH at 15–
20 mg/kg/day could still improve treatment [19]. It is
unclear whether higher doses of RMP could similarly in-
crease the antituberculous activity of RMP. Gumbo and
coworkers demonstrated that rifampicin’s microbial kill-
ing is concentration-dependent and is linked to the ratio
of the area under the concentration-time curve to the
MIC. The suppression of resistance is associated with
the free peak concentration (Cmax)-to-MIC ratio and
not to the duration for which the rifampicin concentra-
tion is above the MIC. In a previous study, rifampicin
was shown to prevent resistance to itself at a free Cmax/
MIC ratio of ≥175 [20], implying that higher doses of ri-
fampicin than those currently employed would optimize
its microbial killing effect, if tolerated by patients. Our
results show that a portion of rifampicin-resistant iso-
lates (38.89%) could be killed by higher concentrations
of rifampicin. The reason for this finding is unclear but
may be related to saturable efflux transporter proteins.
More specifically, the concentration-dependent effects of
rifampicin may be partly explained by what appears to
be enhanced rifampicin entry at higher concentrations
in the bacillary milieu [18,20]. The strains with higher
MICs were found to have a higher frequency of the 531
codon mutation than strains with lower MICs (P <
0.05). These results suggest that mutations in the rpoB
gene are mostly, but not necessarily, associated with
M. tuberculosis rifampicin resistance and that the sites
of the mutations in the rpoB gene may affect the level of
resistance to rifampicin.
In the light of these results, local administration of ri-
fampicin is worth considering to achieve higher concen-
trations. Rifampicin Injection USP was approved by the
FDA on 29 October 1999. However, the clinical use of ri-
fampicin injection in China is still uncommon compared
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was the most widely available drug form when consider-
ing practicability of local chemotherapy. Following the
development of sustained/controlled release techniques,
an implantable drug delivery system for osteoarticular
tuberculosis may have clinical applications in the future.
However, the possibility of the selective enrichment of
rifampicin-resistant bacteria and local toxic effects
needs to be considered.
In summary, the results of the current study suggest
that increasing the rifampicin concentration in tubercu-
lous lesions may optimize the drug’s antituberculous
effect, even for some rifampicin-resistant isolates, as long
as systemic and local toxic effects are minimized. Further
studies may be required to determine the microbial killing
and resistance suppression ability of locally administered
rifampicin.
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